Skip to main content
. 2022 Sep 8;82(21):4058–4078. doi: 10.1158/0008-5472.CAN-22-1731

Figure 7.

Figure 7. Survival analyses for differentially co-mutated KRAS G12C-mutant NSCLC in a cohort of patients treated with chemotherapy and immunotherapy-containing regimens. A, Patients with NSCLC harboring KRAS G12C and STK11 comutations had a shorter overall survival with immunotherapy (n = 24 vs. n = 82, median survival 5.65 vs. 23.52 months, log-rank P = 0.003, HR: 2.31; 95% confidence interval, CI: 1.31–4.07). B, Conversely, co-occurrence of KRAS G12C and TP53 hotspot alterations was associated with longer overall survival with immunotherapy immunotherapy-containing regimens (n = 56 vs. n = 76, median survival 23.52 vs. 10.09 months, log-rank P = 0.05, HR: 0.63, 95% CI: 0.39–1.01). C, KRAS G12C/AMER1 comutations conferred a worse prognosis for patients with metastatic NSCLC treated with immunotherapy-containing regimens (n = 4 vs. n = 128, median survival of 4.55 vs. 12.85 months, log-rank P = 0.029, HR: 2.93, 95% CI: 1.06–8.07). D, Patients with KRAS G12C/PIK3CA-mutant NSCLC (n = 5) had a significantly shorter overall survival compared with patients with KRAS G12C-mutant tumors who received first-line immunotherapy (n = 25, 4.4 months vs. not reached, log-rank P = 0.028, HR: 3.48, 95% CI: 1.07–11.34). IO, immunotherapy.

Survival analyses for differentially comutated KRAS G12C-mutant NSCLC in a cohort of patients treated with chemotherapy and immunotherapy-containing regimens. A, Patients with NSCLC harboring KRAS G12C and STK11 comutations had a shorter overall survival with immunotherapy (n = 24 vs. n = 82, median survival 5.65 vs. 23.52 months, log-rank P = 0.003, HR: 2.31; 95% confidence interval, CI: 1.31–4.07). B, Conversely, co-occurrence of KRAS G12C and TP53 hotspot alterations was associated with longer overall survival with immunotherapy immunotherapy-containing regimens (n = 56 vs. n = 76, median survival 23.52 vs. 10.09 months, log-rank P = 0.05, HR: 0.63, 95% CI: 0.39–1.01). C,KRAS G12C/AMER1 comutations conferred a worse prognosis for patients with metastatic NSCLC treated with immunotherapy-containing regimens (n = 4 vs. n = 128, median survival of 4.55 vs. 12.85 months, log-rank P = 0.029, HR: 2.93, 95% CI: 1.06–8.07). D, Patients with KRAS G12C/PIK3CA-mutant NSCLC (n = 5) had a significantly shorter overall survival compared with patients with KRAS G12C-mutant tumors who received first-line immunotherapy (n = 25, 4.4 months vs. not reached, log-rank P = 0.028, HR: 3.48, 95% CI: 1.07–11.34). IO, immunotherapy.